A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (NCT07284758)
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
Who can join: Review the eligibility criteria below.
Location: Clearview Cancer Institute — Huntsville, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- Clearview Cancer Institute — Huntsville, Alabama
- Mayo Clinic - Arizona — Phoenix, Arizona
- HonorHealth — Scottsdale, Arizona
- Berenson Cancer Center — West Hollywood, California
- Mayo Clinic - Florida — Jacksonville, Florida
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- Indiana University Health — Indianapolis, Indiana
- University of Iowa — Iowa City, Iowa
- Karmanos Cancer Institute — Detroit, Michigan
- START Midwest — Grand Rapids, Michigan
- Mayo Clinic - Minnesota — Rochester, Minnesota
- Washington University/Siteman Cancer Center — St Louis, Missouri
- University of Nebraska Medical Center — Omaha, Nebraska
- The Tisch Cancer Institute/Mount Sinai — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- UNC Hospitals Adult Oncology Clinics — Chapel Hill, North Carolina
- Tennessee Oncology — Nashville, Tennessee
- START San Antonio — San Antonio, Texas
- University of Wisconsin - Carbone Cancer Center — Madison, Wisconsin
- MCW-Clinical Cancer Center at Froedtert Hospital Campus — Milwaukee, Wisconsin
- Imperial College Healthcare NHS Foundation Trust - Hammersmith Hospital — London, United Kingdom
📞 Contact the Study Coordinator
Phone: (617) 231-0700
Email: clinicaltrials@c4therapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.